Drug Targeting TLRs in Cutaneous Lupus Looks Good in Mid-Stage Studies

(MedPage Today) -- Enpatoran, an investigational oral drug that inhibits Toll-like receptors (TLR) 7 and 8, was superior to placebo in relieving lupus skin manifestations in a dose-finding phase II trial. Doses of 25, 50, and 100 mg twice daily...
Source
MedPage Today
Opens original article in a new tab



